Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib
may also stop the growth of liver cancer by blocking blood flow to the tumor.
PURPOSE: This randomized phase I/II trial is studying the best dose of bevacizumab when given
together with sorafenib as first-line therapy in treating patients with locally advanced or
metastatic liver cancer.(Phase I closed to accrual as of 11/03/2010)